News Pfizer suffers another hit to its GBT sickle cell portfolio Pfizer's $5.4 billion takeover of Global Blood Therapeutics three years ago is starting to look like a poor deal.
News Vedanta's microbiome therapy for IBD disappoints Vedanta's microbiome therapy for ulcerative colitis has failed a phase 2 trial and will be shelved, prompting a 20% cut in workforce.
News More good news in Sjogren's as RemeGen trial delivers A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.
News Padcev/Keytruda extends survival in early bladder cancer Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.
News Novartis two for two as ianalumab scores again Novartis' ianalumab has delivered another win in primary immune thrombocytopenia, its second win in autoimmune diseases in 24 hours.
News IO Bio plans cancer vaccine filing despite trial miss IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
